We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Topotecan injection 4mg/4mL intravenous infusion multiple-dose vial (Accord, USA)
Section 19A approved medicine
Topotecan injection 4mg/4mL intravenous infusion multiple-dose vial (Accord, USA)
Section 19A approval holder
Reach Pharmaceuticals Pty Ltd ABN 25 623 897 183
Phone
0422 429 648
Approved until
Status
Current
Medicines in short supply/unavailable
TOPOTECAN ACCORD topotecan (as hydrochloride) 4 mg/4 mL concentrated injection vial - ARTG 310761
Indication(s)
Topotecan Accord concentrated injection is indicated as single agent therapy for the treatment of patients with:
- Small cell lung carcinoma after failure of first line chemotherapy.
Topotecan Accord is indicated in combination with cisplatin for the treatment of patients with:
- Histologically confirmed Stage IV-B, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.
Images
